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Abstract
This thesis describes an experiment that was designed in order to obtain information that
could be useful for treating individuals with HFI. The author hypothesized that MSNBA would
inhibit GLUT5 and fructose metabolism in the small intestine. The final experimental design
involves exposing a small intestine cell line to fructose and MSNBA. The cell line would be
exposed to MSNBA over the course of three different periods, and data was intended to be
obtained using western blotting and a fructose assay kit. Although the final experimental design
project was not fully carried out due to circumstances surrounding COVID-19, a plausible
experimental design was produced. The experimental design has the potential to be modified in
ways that could be used to test the effects of MSNBA with more informative results. The
modifications could be used to plan a study that could obtain more useful data than the final
experimental design described in this work.
Keywords:hereditary fructose intolerance, MSNBA, GLUT5, western blotting, fructose
metabolism, fructose malabsorption, FHs 74 Int
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GLUT5 and Fructose Metabolism Inhibition in a Simulated Small Intestine Environment
This project was designed to obtain data regarding the inhibition of fructose metabolism
in the small intestine, and the objective of this experiment was to study potential treatments for
disorders like hereditary fructose intolerance (HFI).
Fructose Metabolism Disorders
Unfortunately, not everyone can digest fructose. In fact, Tran (2017) has found that there
are three types of disorders in fructose metabolism. These disorders are called essential
fructosuria, fructose-1,6-bisphosphatase (FBPase) deficiency, and hereditary fructose
intolerance. Essential fructosuria has no symptoms and is not usually treated. FBPase
deficiency and HFI are potentially life-threatening disorders caused by exposure to fructose,
sucrose, and/or sorbitol (Baker et al., 2015; Tran, 2017). FBPase and essential fructosuria will
not be discussed further in this work.
Potentially deadly disorders like HFI are concerning because fructose is so common. In
fact, Baker et al. (2015) states that nuts, wax beans, green beans, potatoes, onions, spinach,
cabbage, lettuce, asparagus, celery, and cauliflower are the few vegetables that people with HFI
are recommended to eat because all other vegetables contain fructose. Additionally, fruits and
foods with added sugars are considered prohibited in HFI dietary guidelines. Limitations
regarding medication use are also present due to the presence of fructose in intravenous
medications. Needless to say, fructose is quite prevalent in daily existence.
In addition to the hardships that can come with such dietary restrictions, HFI is a
worrisome disorder because there is no cure for it (Baker et al., 2015). The fact that a disorder
with a potentially heavy impact on people’s lives has no cure interested the author, and further
steps were taken to learn more about fructose metabolism.

4
Hereditary Fructose Intolerance
HFI is a genetic disorder that causes the production of a malfunctioning version of an
enzyme called Aldolase B (Baker et al., 2015). According to Cox (2009), Aldolase B is essential
for fructose metabolism, and it can be found in the kidneys, liver, upper small intestine, and the
duodenum of the small intestine. Normally, ingested fructose is absorbed using facilitated
diffusion by cells in the mucous membrane of the small intestine through GLUT5 and converted
into fructose 1-phosphate by fructokinase. Next, Aldolase B cleaves fructose 1-phosphate into
glyceraldehyde and dihydroxyacetone phosphate for further processing in glycolysis and
gluconeogenesis. This mechanism, as illustrated in Figure 1 on the next page, primarily takes
place in the small intestine, and excess fructose that cannot be chemically altered by the organ
is transported to the liver through the hepatic portal vein (Jang et al., 2018).
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Figure 1
Fructose Metabolism Comparison

Note.The information used to make this figure is from Cox (2009) and Gericke et al. (2017). The figure
illustrates fructose metabolism in the small intestine when Aldolase B does and does not function
properly. Sorbitol is converted into fructose by sorbitol dehydrogenase in the lumen (Cox, 2009).
Sucrase-isomaltase—an enzyme usually embedded in the cell membrane of small intestine
cells—hydrolyzes the α-1,2-glucosidic bonds of sucrose to produce fructose (Gericke et al., 2017).

Cox (2009) states that fructose 1-phosphate accumulates in the body when Aldolase B is
unable to cleave it. Aldolase A and phosphorylase A are competitively inhibited by fructose
1-phosphate, and this halts gluconeogenesis and glycolysis, respectively. A variety of
detrimental effects also occur (Cox, 2009). One of these effects is a harsh drop in the amount of
glucose in the blood (Tran, 2017). Baker et al. (2015) explain that HFI initially manifests with
symptoms of nausea, abdominal distress, vomiting, and inability to grow. These symptoms tend
to be experienced by infants starting to eat food containing fructose or sucrose; they can
experience more serious clinical manifestations—seizures, lethargy, and/or progressive
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coma—after eating a large amount of fructose. People who are continuously exposed to
fructose, sucrose, and/or sorbitol can suffer from kidney damage and liver damage extensive
enough to cause kidney failure and/or liver failure. The only way to avoid the symptoms of HFI is
to abstain from foods and medications containing fructose, sucrose, and/or sorbitol. Due to
dietary restrictions, individuals with HFI consume fewer varieties of vegetables and fruits;
therefore, to prevent nutrient deficiencies, multivitamins must be used. For instance,
supplements for vitamin C have been recommended (Guery et al., 2007). Those individuals
affected by HFI also would need to abstain from foods containing polysorbate and sucralose
(Baker et al., 2015).
GLUT5
GLUT5 is a type of transporter belonging to a family of 14 glucose transporters (GLUT)
(Douard & Ferraris, 2008), and isoform 1 of GLUT5 is 501 amino acids long (National Center for
Biotechnology Information & U.S. National Library of Medicine, n.d.-a). GLUT5 is 54,973.98 Da
(Swiss Institute of Bioinformatics, n.d.), which is around 54.97 kDa. This molecular weight was
found by taking the amino acid sequence from the National Center for Biotechnology
Information and the U.S. National Library of Medicine (n.d.-a) and inputting it into the ProtParam
tool provided by the Swiss Institute of Bioinformatics (n.d.). Isoforms 2, 3, and 4 are 244, 457,
and 354 amino acids long, respectively (National Center for Biotechnology Information & U.S.
National Library of Medicine, n.d.-b, n.d.-c, n.d.-d). Isoforms 2, 3, and 4 are likely to be
fragments because GLUT5 is 501 amino acids long in general (InterPro, n.d.).
GLUT5 (synonymous with Slc2a5) lines the small intestine to bring fructose into small
intestine cells (Ebert et al., 2017). It is also found in smaller quantities in the skeletal muscle,
brain, kidney, testes, and adipose tissue (Nomura et al., 2015). Despite the name of the family it
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belongs to, GLUT5 is unable to transport glucose (Douard & Ferraris, 2008). GLUT5 has been
found to be essential for fructose metabolism in mice because mice without the GLUT5
transporter experienced an inability to digest fructose (Barone et al., 2009).
GLUT5 has also been found to be important in cancer research. For instance, multiple
types of cancer cells express a high amount of GLUT5 due to their need for a high amount of
sugar (Nomura et al., 2015). In fact, George Thompson et al. (2016) writes that breast cancer
cell lines MCF7 and MDA-MB-231 take in fructose and contain mRNA that encodes for GLUT5.
In contrast, cells that make up breast tissue do not usually have GLUT5. Cancerous cells in the
uterus, testis, colon, lung, liver, and brain have been shown to express high levels of GLUT5 as
well (Douard & Ferraris, 2008).
GLUT5 Inhibition
A few experiments studied chemicals that could hamper GLUT5. For instance, Caco-2
cells, cells resembling human intestinal epithelia, were exposed to three phytochemicals called
nobiletin, epicatechin gallate (ECg), and tangeretin, and the treated cells absorbed fructose at a
rate that was 60% of the untreated cells (Satsu et al., 2018). Another study found that
astragalin-6-glucoside, a plant product, inhibited GLUT5 function without affecting GLUT1
(George Thompson et al., 2015). A third experiment found that
N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA) inhibited GLUT5
exclusively in MCF7 cells (George Thompson et al., 2016).
The author of this paper decided to work on an experimental design around MSNBA
because the study from George Thompson et al. (2016) showed that MSNBA specifically
affected GLUT5. In contrast, the study by George Thompson et al. (2015) focused on the effects
that plant products had on GLUT1 and GLUT5 without investigating GLUT2, 3, and 4 to the
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extent that the George Thompson (2016) study did. The Satsu et al. (2018) study, which
concentrated on the effects of plant phytochemicals on nutrient uptake, also did not investigate
GLUT2, 3 and 4 to the same degree as the George Thompson (2016) study.
Other Design Choices
At first, the experimental design was concentrated on supplementing the small intestine
with functional Aldolase B; however, this plan proved to not be feasible. Plans were then made
for a project studying methods of halting fructose absorption.
Two Designs
The hypothesis of the first experimental design was that supplementing the small
intestine lumen with Aldolase B would increase the rate of fructose digestion in the cells. This
design could not be carried out for multiple reasons. The main reason is that Aldolase B cleaves
fructose 1-phosphate instead of fructose (Cox, 2009), so adding Aldolase B in a small intestine
environment would not affect fructose digestion. Sibley and Lehninger’s (1949) journal was the
source for the assay described in the first design. However, their work investigated the
concentration of the products made by the breakdown of fructose 1,6-bisphosphate in tissues,
which are glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. Although Aldolase B
reacts to fructose 1,6-bisphosphate and fructose 1-phosphate in equal rates (Cox, 2009),
glyceraldehyde 3-phosphate and glyceraldehyde are not the same compounds, so the
procedure written by Sibley and Lehninger (1949) would not have provided any data that could
support or falsify the original hypothesis. More details about this initial design can be found in
Appendix 1: Aldolase B in the Small Intestine.
After further literature research, the author altered the experiment’s approach. The new
procedure involved impairing the function of GLUT5. Because MSNBA was shown to
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specifically prevent GLUT5 from importing fructose in breast cancer cells (George Thompson et
al., 2016), the project’s efforts went towards investigating MSNBA’s effects on GLUT5 in small
intestine cells. After all, the small intestine has conditions that differ from those of breast cancer
cells. When the author created the second experimental design, no studies had been published
containing information on MSNBA’s effects on the small intestine, so plans for the project were
formulated as soon as that information was known. It was hypothesized that MSNBA would halt
fructose metabolism in small intestine cells by inhibiting the function of the GLUT5 transporter
as demonstrated in Figure 2.
Figure 2
MSNBA on GLUT5

Note. T
 his figure was created from information and illustrations in Nomura et al. (2015) and George
Thompson et al. (2016). Because George Thompson et al. (2016) found that MSNBA inhibits GLUT5
competitively, the author of this project created the above figure to show how MSNBA has the potential to
prevent facilitated diffusion of fructose via GLUT5 in the small intestine.
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Protein Analysis
It was decided that the amount of GLUT5 proteins would be obtained via a process
called western blotting instead of through any tests on mRNA translation. The study from
George Thompson et al. (2016) showed that MSNBA competitively inhibits GLUT5. Specifically,
the study showed that MSNBA directly affects the GLUT5 protein; however, it does not prevent
the production of the transporter. According to Mahmood and Yang (2012), western blotting
uses gel electrophoresis to separate proteins. The gel is stacked onto the membrane, which
allows the proteins to move successfully onto the membrane. At this point, the proteins are
gathered in the form of bands. Next, the membrane is first exposed to a primary antibody that
binds to the protein of interest and is then exposed to a secondary antibody. Once the
secondary antibody binds to the primary antibody, the band bound to the primary antibody is
detectable (Thermo Fisher Scientific Inc., n.d.-b). After the band is detectable, one can ascertain
how much protein is found in the sample based on how thick the band is (Mahmood & Yang,
2012).
Fructose Kit
The author planned to use a High Sensitivity Fructose Assay Kit from Sigma-Aldrich® to
detect the amount of fructose in a sample of cells; using a kit would be less difficult than
attempting to create a new method for investigating whether fructose was imported inside of the
small intestine cells. The author planned to use a coupled enzyme assay kit (Sigma-Aldrich Co.
LLC, 2014). As Eilertsen and Schnell (2018) explain, a coupled enzyme assay consists of two
reactions; the first reaction uses an enzyme to convert the substrate into the first product.
Another enzyme is then used to convert the first product into a second product. In the case of
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this assay, the second product is fluorescent (Sigma-Aldrich Co. LLC, 2014), so it gives off light
at a particular wavelength when it is exposed to light (Thermo Fisher Scientific Inc., n.d.-a).
Experimental Design
This experiment could not be attempted due to circumstances described in the section,
Experimental Attempt. Consequently, despite the author’s efforts to provide exact details on
how that experiment could be conducted, some methods of that experiment likely need to be
modified. Without performing the experiment, there is no certain way of knowing what parts of
the design, if any, should be altered and what the alterations would look like.
Final Design
Cell Culture. In the second experimental design, the author planned to use a simulated
small intestine environment made by using Fhs 74 Int cells, a small intestine cell line from
ATCC® and by following instructions posted at American Type Culture Collection (2019).
According to manufacturer’s instructions, FHs 74 Int cells would be grown and maintained in
100 mm cell culture plates in ATCC® Hybri-Care Medium supplemented with 30 ng/mL human
epidermal growth factor (HEGF) and fetal bovine serum. The HEGF would be supplied from
Gibco™. Based on a discussion with Gabriel Almeida Alves, a current PhD candidate in Biology
at Western Michigan University, the author agreed that Gibco™ 100X Antibiotic-Antimicotic
would also be supplemented in the growth media. 100 mm cell culture plates are estimated to
contain 5.5 × 106 cells (American Type Culture Collection, 2014), and this plate size would allow
enough cells to grow to provide a sample for the fructose assay kit.
Treatment. Individual cell culture plates would be grouped according to the treatment
they would receive. Because digestion is not instantaneous and occurs over time, periods of
treatment would occur for 0 minutes, 30 minutes, 2 hours, or 24 hours. To investigate the effects
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of MSNBA on fructose metabolism, FHs 74 Int cells in plates would be divided into groups
based on exposure to either 0 µM, 50 µM, 100 µM, or 200 µM concentrations of MSNBA
dissolved in dimethyl sulfoxide (DMSO) and to exposure to a fructose solution or a solution
lacking fructose. The MSNBA would be supplied by Enamine, and the fructose solution would
consist of 10 mM fructose dissolved in ATCC® Hybri-Care Medium without any additional
supplements. The number of plates per group would have been decided based on the amount
of supplies available. The treatments would have been administered to plates in the manner
described in Table 1.
Table 1
Volume of Treatment
Solution

Treatment Group
TG 4
TG 5
TG 6

TG 1

TG 2

TG 3

TG 7

TG 8

50 μM MSNBA

100

0

0

0

100

0

0

0

100 μM MSNBA

0

100

0

0

0

100

0

0

200 μM MSNBA

0

0

100

0

0

0

100

0

10 mM Fructose

200

200

200

200

0

0

0

0

Media without the
Supplements

200

200

200

200

400

400

400

500

Note.Table 1 provides the volume of the treatment solution that would be added to each plate in an
assigned treatment group of cell culture plates. The total volume for these treatment solutions would be
500 µL each. All volumes in this table are in microliters. TG stands for “Treatment Group.” TG 4 was the
control for the small intestine cells exposed to a fructose solution, and TG 8 was the control for all of the
TGs.
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The cycle of treatments would be repeated to obtain enough protein for the western
blotting assay and enough of a supernatant for the fructose assay.
Western Blotting. The lysate would have been prepared according to instructions found
in a tutorial created by NovusBiologicals (2012). As stated in the tutorial by NovusBiologicals
(2012), the cells would be washed in ice-cold PBS twice, covered with lysis buffer, and scraped
into a centrifuge tube in an ice bucket. The cells would be pipetted up and down, and the
centrifuge tube would be left to rest in the ice bucket for 30 minutes. Once that incubation period
is complete, the centrifuge tube would be centrifuged to produce a cell pellet and a supernatant,
and the supernatant would be collected while the pellet would be discarded. The only
modification to the steps of the tutorial would be that a CHAPS lysis buffer would be prepared
using instructions from “CHAPS Lysis Buffer” (2014) instead of using a RIPA buffer mentioned
in the tutorial provided by NovusBiologicals (2012). CHAPS would be used because it can
separate membrane proteins from the membrane (Lorch & Batchelor, 2011).
10% mini polyacrylamide gels would be used because they can separate proteins
weighing between 15-100 kDa (Abcam, n.d.). The mini polyacrylamide gels would be made
using a protocol from Life Technologies Corporation (2014). The samples would be placed in
the wells of mini polyvinylidene difluoride (PVDF) membranes with 0.45 µm pores, which is the
appropriate pore size for proteins larger than 20 kDa (Li-COR, 2020). Based on a discussion
with Jaafar Hachem, a current PhD candidate in Chemistry at Western Michigan University, a
5% fat-free bovine serum albumin (BSA) solution would be used as the blocking buffer for the
immunoblotting process, and a tris-buffered saline-Tween (TBST) solution would be used to
wash the membrane.
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A rabbit anti-human GLUT5 polyclonal antibody from Thermo Fisher Scientific Inc.
(Catalog # PA5-82190) would be used for the primary antibody, and a goat anti-rabbit IgG (H+L)
highly cross-adsorbed secondary antibody (Alexa Fluor Plus 488) (Catalog # A32731) from
Thermo Fisher Scientific Inc. would also be used. The membrane would be incubated in a
chemiluminescent reagent.
Fructose Assay. A High Sensitivity Fructose Assay Kit from Sigma-Aldrich® would be
used to determine the extent to which fructose metabolism would have occurred. The kit would
be used according to the protocol written by Sigma-Aldrich Co. LLC (2014). That protocol states
that the end product of the coupled enzyme assay should give off light at 587 nm when exposed
to light at a wavelength of 535 nm. The kit is capable of detecting as little as 20-100 pmole/well
of D-fructose. Each sample would consist of 1-50 µL of the supernatant from 5 × 106 cells
centrifuged at 13,000 × gand mixed in ice-cold phosphate-buffered saline at a pH of around 8,
and the samples would be administered in wells of a 96 well flat-bottom plate. The concentration
of the fructose would be calculated using equations listed in the Sigma-Aldrich Co. LLC (2014)
protocol.
Experiment
Once the final plans for the experiment were drafted, the author attempted to make a
growth environment suitable for the small intestine cells. During this period, materials were
being gathered and prepared for the cells. However, safety concerns related to the 2020
COVID-19 pandemic resulted in the cessation of further progress as the laboratory where the
experiment was being conducted was eventually closed to students. Because the experiment
was never completed, this section details what was accomplished. After this stage, supplies
were being gathered, and manufacturers were being called to ask for help with some
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last-minute questions. The ATCC® FHs 74 Int cells, ATCC® Hybri-Care Medium, Gibco™ 100X
Antibiotic-Antimicotic, and fetal bovine serum were acquired. The ATCC® Hybri-Care Medium
was also reconstituted and filtered with a 0.22 µm filter.
Additionally, because the Gibco™ HEGF was required, the author was about to
purchase it, but could not successfully login to the vendor’s website at the time. Consequently, a
price quote for the item and an eventual purchase could not be made. Shortly after those events
took place, the project was stopped because Western Michigan University ceased all in-person
lectures and class laboratory activities. Due to the pandemic, it became clear that the likelihood
of the author continuing to work on the project would be extremely low.
Discussion
If this project is attempted in the future, modifications could be made to provide a more
realistic model of the human body. The first modification would be to use different doses and
concentrations of sugars. Additionally, an animal model could be used to achieve more
comprehensive results than what could be achieved using a cell line.
Modification 1
This project was designed to use a 10 mM fructose solution. However, because
individuals eat varying amounts of fructose, only so much information can be inferred from this
project. Additionally, future attempts with MSNBA testing could be done with a mixture of
fructose, sucrose, and/or sorbitol. A caveat to using different combinations and doses of sugar
is that individuals eat different quantities of sugar worldwide, so figuring out how much sugar
can or should be used to test the effectiveness of MSNBA could be difficult.
Rao et al. (2007) found that the uppermost limit for a single dose of fructose could be 50
g because healthy participants in their study who consumed that much fructose in one serving
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exhaled more hydrogen than the baseline value. This result is a sign of fructose malabsorption.
Ozaki et al. (2018) found that fructose that is not taken into the intestine is left to be fermented
by bacteria into gases like hydrogen and short-chain fatty acids, and this hydrogen can enter the
bloodstream and be exhaled out in measurable quantities. Fructose malabsorption can lead to
fructose intolerance, which Ozaki et al. (2018) defines as a series of abdominal issues such as
vomiting, gas, diarrhea, abdominal pain, abdominal distension, and nausea. Rao et al. (2007)
found that among participants who drank a 10% (w/v) solution with 50 g of fructose, 69%
experienced an increase in the exhalation of hydrogen, and portions of this group stated that
they had such symptoms as gas (30%), diarrhea (15%), and abdominal pain (15%). The authors
also found that a portion of healthy individuals experienced some of the symptoms that Ozaki et
al. (2018) has noted to be indicative of fructose intolerance. Therefore, 50 g could be used as
an upper benchmark for a single dose of fructose.
As for the lowest single dose of fructose, two things could be considered. First, data from
Rao et al. (2007) indicated that healthy individuals who consumed 15 g of fructose did not
experience any symptoms of fructose malabsorption or an increase in hydrogen exhalation.
Additionally, a regular soft drink can contain approximately 20 g of fructose (Douard & Ferraris,
2013). Considering that Rao et al. (2007) found that a healthy individual does not experience
malabsorption when consuming 15 g of fructose, 15 g could be categorized as a low benchmark
for fructose dosing because that quantity can be surpassed with 1 soft drink.
Modification 2
One of the major modifications to the project would be to use a mouse model instead of
a cell line model. If in vitrotests show promising results, then in vivostudies could be conducted
using, for example, GLUT5 knockout mice similar to what Barone et al. (2009) used in their
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GLUT5 research. To have a more detailed idea of the extent to which MSNBA inhibits GLUT5
metabolism, comparisons could be done between 1) GLUT5 knockout mice with MSNBA
administered to them, 2) GLUT5 knockout mice with no MSNBA administered to them,
3) wild-type mice with MSNBA administered to them, and 4) wild-type mice with no MSNBA
administered to them. Further data could be acquired with Aldolase-B knockout mice, which
have been found to experience effects similar to humans affected by HFI (Oppelt et al., 2015).
The use of a mouse model would incorporate certain variables that the use of a cell
model would not account for. For instance, the pH of the small intestine has been found to vary
from a range of 5.9—6.3, in the beginning of the organ, to a range of 7.4—7.8, towards the end
of the organ (Koziolek et al., 2015).
The current cell model design does not completely replicate the conditions of the human
small intestine, which is why a mouse model could provide more pertinent data for a project of
this nature. Compared to the media used to grow the cells in the current design, the human
small intestine, as Koziolek et al. (2015) note, has a fairly wide pH range throughout the organ.
When ATCC® Hybri-Care Medium is prepared as per the instructions of American Type Culture
Collection (2018), the pH range should be 7.0-7.4. Because the pH range of the growth media
matches that of only a portion of the small intestine, a mouse model would likely provide more
information about how MSNBA would affect the small intestine.
A mouse model could also provide a microbiome that would produce a more accurate
representation of the interstitial fluid to which the MSNBA and small intestine epithelium would
be subjected. A microbiome is crucial because MSNBA has the potential to cause fructose
malabsorption. Due to MSNBA’s properties as a competitive inhibitor (George Thompson et al.,
2016), inhibiting the function of GLUT5 could cause fructose to stay in the lumen of the small
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intestine to ferment. After all, the gut is far from sterile, and Payne et al. (2012) notes that the
gut contains Lactobacillus, Bifidobacterium, and Faecalibacterium, which are all bacteria
capable of processing fructose. Since the fermentation of fructose can lead to symptoms of
fructose malabsorption and intolerance (Ozaki et al., 2018), some considerations might need to
be made if future evidence supports the idea that the substance could be used as a drug for
those with HFI. Specifically, the patient’s level of comfort should be accounted for in case
symptoms of fructose malabsorption and intolerance manifest.
Conclusion
This experiment was designed in order to obtain information that could be useful for
treating individuals with HFI. It was hypothesized that MSNBA would inhibit GLUT5 and fructose
metabolism in the small intestine. Although this project was not fully carried out, a plausible
experimental design was produced. Had this experiment been attempted, the design could have
been modified to test the effects of MSNBA, which could have provided more informative
results. These alterations could have been used to plan a study that could obtain more useful
data than the final experimental design described in this work.
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Appendix 1: Aldolase B in the Small Intestine
This portion of the work details the initial design for this project, and it was not
implemented because it proved to not be feasible. The exact details for the design such as the
names of the products that would have been purchased are not provided because the author
realized that the design was not feasible during the process of organizing its implementation.
Cell Culture
The cell culture methods for Aldolase B in the Small Intestine would be the same as the
methods used in GLUT5 and Fructose Metabolism Inhibition in a Simulated Small Intestine
Environment.
Treatment
Individual cell culture plates would be exposed to Aldolase B and fructose. One group of
plates would be exposed to fructose without any Aldolase B. Another group of plates would be
exposed to Aldolase B without being exposed to fructose. A final group of plates would be
exposed to Aldolase B and fructose. The details for this section were not completed because
the author learned while attempting to make plans for this design that this method would not
answer the first hypothesis.
Assay
The data would be gathered using an assay that would require the use of methods
written by Sibley and Lehninger (1949), which would require the use of a photoelectric
colorimeter. As per the procedure written by Sibley and Lehninger (1949), the sample would be
mixed with 0.25 mL of fructose 1,6-bisphosphate and 0.25 mL of a hydrazine solution in a
test-tube. The test-tube would also contain 1 mL of 0.1 M tris(hydroxymethyl)aminomethane
buffer and would be filled with enough deionized water to bring the total test tube volume to 2.5
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mL of solution. The test-tube would be placed in a water bath set at 38°C for 30 minutes. To
stop the chemical reaction of the sample, 2 mL of 10% trichloroacetic acid would be used. A
blank test tube would be prepared for each sample by repeating the preparations described
above without adding fructose 1,6-bisphosphate until after the reaction.
Continuing to pattern the methods developed by Sibley and Lehninger (1949) all test
tubes would be centrifuged, and 1 mL of the supernatant for each tube would be placed in
colorimeter tubes in order to obtain a reading. The colorimetric tubes would be placed in a 38°C
water bath for 10 minutes after 1 mL of 2,4-dinitrophenylhydrazine solution is added to it. The
colorimeter would be set at 100% for its transmission when the experimental sample is
measured, and a standard curve would be generated to show how the percent transmission is
affected by the amount of fructose 1,6-bisphosphate that is split. The color released has a
maximum absorption of 540 nm. The enzyme concentration should be calculated based on the
fact that the concentration is proportional to the intensity of the color.

